Back to Search Start Over

An Alzheimer's disease risk variant in TTC3 modifies the actin cytoskeleton organization and the PI3K-Akt signaling pathway in iPSC-derived forebrain neurons.

Authors :
Cukier HN
Duarte CL
Laverde-Paz MJ
Simon SA
Van Booven DJ
Miyares AT
Whitehead PL
Hamilton-Nelson KL
Adams LD
Carney RM
Cuccaro ML
Vance JM
Pericak-Vance MA
Griswold AJ
Dykxhoorn DM
Source :
Neurobiology of aging [Neurobiol Aging] 2023 Nov; Vol. 131, pp. 182-195. Date of Electronic Publication: 2023 Jul 17.
Publication Year :
2023

Abstract

A missense variant in the tetratricopeptide repeat domain 3 (TTC3) gene (rs377155188, p.S1038C, NM_003316.4:c 0.3113C>G) was found to segregate with disease in a multigenerational family with late-onset Alzheimer's disease. This variant was introduced into induced pluripotent stem cells (iPSCs) derived from a cognitively intact individual using CRISPR genome editing, and the resulting isogenic pair of iPSC lines was differentiated into cortical neurons. Transcriptome analysis showed an enrichment for genes involved in axon guidance, regulation of actin cytoskeleton, and GABAergic synapse. Functional analysis showed that the TTC3 p.S1038C iPSC-derived neuronal progenitor cells had altered 3-dimensional morphology and increased migration, while the corresponding neurons had longer neurites, increased branch points, and altered expression levels of synaptic proteins. Pharmacological treatment with small molecules that target the actin cytoskeleton could revert many of these cellular phenotypes, suggesting a central role for actin in mediating the cellular phenotypes associated with the TTC3 p.S1038C variant.<br />Competing Interests: Disclosure statement The authors report no conflict of interest.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1558-1497
Volume :
131
Database :
MEDLINE
Journal :
Neurobiology of aging
Publication Type :
Academic Journal
Accession number :
37677864
Full Text :
https://doi.org/10.1016/j.neurobiolaging.2023.07.007